Natera(US:NTRA)2025-11-06 21:30Financial Performance - Q3 2025 revenue reached approximately $592 million, a year-over-year increase of about 35% compared to approximately $440 million in Q3 2024[8] - Approximately 894,000 total tests were processed in Q3 2025, reflecting a year-over-year growth of about 15% from approximately 776,000 in Q3 2024[8] - Clinical MRD tests numbered approximately 202,000 in Q3 2025, a year-over-year increase of about 56% from approximately 130,000 in Q3 2024[8] - Gross margin was approximately 65% in Q3 2025, with approximately $26 million in cash inflow generated[8] - The 2025 financial outlook was increased by $160 million, projecting revenue between $218 billion and $226 billion, gross margin between 62% and 64%, and $100 million in cash flow generation[8] Product Development and Data - A newly expanded 20-gene panel for Fetal Focus is launching in Q4[29] - Early cancer detection data for advanced adenomas was announced[8] - Strong Signatera data was presented at ESMO, reinforcing MRD leadership[8] Clinical Data and Studies - ESMO Congress presented practice-changing evidence in muscle-invasive bladder cancer[33] - Strong Signatera data in colorectal cancer was presented at ESMO, with a publication in Nature[36] - Overall advanced adenoma performance showed 225% sensitivity (CI: 154%-324%) and 915% specificity (CI: 882%-939%)[44]